Tesamorelin

One of the few peptides with full FDA approval. Demonstrated visceral fat reduction in RCTs. Off-label use in anti-aging is growing but not approved for that indication.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Pivotal RCTs demonstrated significant visceral adipose tissue reduction in HIV lipodystrophy. Also studied for NAFLD/NASH and cognitive function. Well-characterized safety profile.

• FDA-approved with robust RCT evidence
• Significant visceral fat reduction demonstrated
• Improved IGF-1 and trunk fat ratio
• Possible NAFLD improvement in early data

Egrifta: 2 mg subcutaneously once daily.

• Injection-site reactions (erythema, pruritus)
• Peripheral edema
• Arthralgia
• Myalgia
• Elevated IGF-1

FDA-approved for HIV lipodystrophy only. Contraindicated in pituitary disease and active malignancy. Fluid retention possible.

Efficacy proven for HIV lipodystrophy. Off-label anti-aging use extrapolates from a different patient population.

• Weight loss50
• Muscle35
• Longevity28